239 related articles for article (PubMed ID: 31319147)
41. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D
J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365
[TBL] [Abstract][Full Text] [Related]
42. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
[TBL] [Abstract][Full Text] [Related]
43. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
44. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk.
Balaian L; Ball ED
Leukemia; 2006 Dec; 20(12):2093-101. PubMed ID: 17051243
[TBL] [Abstract][Full Text] [Related]
45. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
[TBL] [Abstract][Full Text] [Related]
46. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
[TBL] [Abstract][Full Text] [Related]
47. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL.
Ross DD; Wooten PJ; Tong Y; Cornblatt B; Levy C; Sridhara R; Lee EJ; Schiffer CA
Blood; 1994 Mar; 83(5):1337-47. PubMed ID: 8118035
[TBL] [Abstract][Full Text] [Related]
48. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
Xie LH; Biondo M; Busfield SJ; Arruda A; Yang X; Vairo G; Minden MD
Blood Cancer J; 2017 Jun; 7(6):e567. PubMed ID: 28574487
[TBL] [Abstract][Full Text] [Related]
49. Contrastive Studies of Cytarabine/Daunorubicin Dual-Loaded Liposomes Prepared by pH Gradient and Cu
Zhang J; Zhou L; Zhang Y; He H; Yin T; Gou J; Wang Y; Tang X
AAPS PharmSciTech; 2020 Nov; 21(8):325. PubMed ID: 33206247
[TBL] [Abstract][Full Text] [Related]
50. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
51. In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB; Wickstroem K; Wang E; Shea AO; Sponheim K; Karlsson J; Bjerke RM; Ryan OB; Cuthbertson AS
Mol Cancer Ther; 2016 Oct; 15(10):2422-2431. PubMed ID: 27535972
[TBL] [Abstract][Full Text] [Related]
52. Altered intracellular distribution of daunorubicin in immature acute myeloid leukemia cells.
Lautier D; Bailly JD; Demur C; Herbert JM; Bousquet C; Laurent G
Int J Cancer; 1997 Apr; 71(2):292-9. PubMed ID: 9139856
[TBL] [Abstract][Full Text] [Related]
53. Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Imrichova D; Messingerova L; Seres M; Kavcova H; Pavlikova L; Coculova M; Breier A; Sulova Z
Eur J Pharm Sci; 2015 Sep; 77():29-39. PubMed ID: 26002042
[TBL] [Abstract][Full Text] [Related]
54. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
Baroni ML; Sanchez Martinez D; Gutierrez Aguera F; Roca Ho H; Castella M; Zanetti SR; Velasco Hernandez T; Diaz de la Guardia R; Castaño J; Anguita E; Vives S; Nomdedeu J; Lapillone H; Bras AE; van der Velden VHJ; Junca J; Marin P; Bataller A; Esteve J; Vick B; Jeremias I; Lopez A; Sorigue M; Bueno C; Menendez P
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates.
Li B; Zhao W; Zhang X; Wang J; Luo X; Baker SD; Jordan CT; Dong Y
Bioorg Med Chem; 2016 Nov; 24(22):5855-5860. PubMed ID: 27687970
[TBL] [Abstract][Full Text] [Related]
56. Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 study.
Usui N; Takeshita A; Nakaseko C; Dobashi N; Fujita H; Kiyoi H; Kobayashi Y; Sakura T; Yahagi Y; Shigeno K; Ohwada C; Miyazaki Y; Ohtake S; Miyawaki S; Naoe T; Ohnishi K;
Cancer Sci; 2011 Jul; 102(7):1358-65. PubMed ID: 21585619
[TBL] [Abstract][Full Text] [Related]
57. Osteopontin plays a unique role in resistance of CD34+/CD123+ human leukemia cell lines KG1a to parthenolide.
Mohammadi S; Zahedpanah M; Ghaffari SH; Shaiegan M; Nikbakht M; Nikugoftar M
Life Sci; 2017 Nov; 189():89-95. PubMed ID: 28935249
[TBL] [Abstract][Full Text] [Related]
58. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
[TBL] [Abstract][Full Text] [Related]
59. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
Eckel AM; Cherian S; Miller V; Soma L
Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
[TBL] [Abstract][Full Text] [Related]
60. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS.
Xiong S; Yu B; Wu J; Li H; Lee RJ
Biomed Pharmacother; 2011 Feb; 65(1):2-8. PubMed ID: 21177069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
